– Partner Curasense will market Equazen® products featuring a clinically researched combination of essential fatty acids across pharmacies, healthcare stores and online pharmacies.
SFI Health™ EMEA, the regional entity of SFI Health™, a global leader in natural healthcare, and Curasense BV (Curasense), a Belgian company specializing in the distribution and development of high-quality nutraceuticals and health products, are excited to announce that they have entered into an exclusive licensing agreement for Equazen® food supplements in the Netherlands and Belgium.
Under the terms of the agreement, Curasense will hold exclusive rights to distribute, promote, market, and sell Equazen® products within the licensed territories. Curasense will begin commercial activities following a transition period from SFI Health™’s previous licensee.
Together, Belgium and the Netherlands count over 6,500 pharmacies, alongside a strong presence of health stores — from 800 independents in Belgium to 2,000 outlets in the Netherlands. With well-established pharmacy and retail networks, plus growing online demand, the agreement positions the brand for strong visibility and reach across both markets.
Matthew Brabazon, GM of SFI Health™ EMEA commented: “We are very pleased to collaborate with Curasense, a company with extensive experience in the healthcare sector and a strong reputation among healthcare professionals and consumers. This partnership marks an important step in strengthening the Equazen® brand, as we leverage Curasense BV’s expertise in bringing advanced scientifically naturally sourced health solutions to market. Together, we are committed to expand Equazen®’s distribution and market share, establishing it as a reference point for brain health and cognitive wellness.”
Mr. Jelle D’Helft, CEO of Curasense, added: “We are thrilled to formalize our strategic partnership with SFI Health™ EMEA for the Equazen® brand in the Netherlands and Belgium. For Curasense, this agreement is a natural extension of our mission to deliver evidence-based health solutions that make a real impact. Equazen®’s clinically supported formulations align closely with our vision and reflect our ambition to bridge conventional and complementary medicine. This collaboration will accelerate access to innovative, science-backed products for children, adolescents, and adults—while setting new benchmarks in the nutraceutical industry.”
The brain health supplement sector is emerging as one of the most dynamic segments within the global food supplements market. In Europe, it is expected to grow at a CAGR of 12.5% from 2023 to 2030, supported by increasing consumers’ focus on sustaining normal cognitive function and mental health.
Equazen® is currently present in several EMEA markets, including Spain, Portugal, the United Kingdom, Switzerland, Poland, the Czech Republic, Slovakia, the Nordics, and the Baltics, with SFI Health™ aiming to broaden its reach into new markets to unlock its full sales potential and capitalize on the growing momentum in the brain food supplements sector.
